Celgene Corp has posted another impressive set of financials for the fourth quarter, driven by strong performances of its multiple myeloma drugs Revlimid and Pomalyst.

Adjusted net income rose 29% to $840 million, while sales increased 19% to $2.06 billion. Revlimid (lenalidomide), which is also approved for myelodysplastic syndromes (MDS), generated $1.32 billion, up 16%, while Pomalyst/Imnovid (pomalidomide) brought in $202 million, up 67%.

The breast, pancreatic and lung cancer drug Abraxane (nab-paclitaxel) saw sales climb 17% to $236 million, while the new psoriasis and psoriatic arthritis drug Otezla (apremilast) contributed nearly $48 million. Vidaza (azacitidine), which is approved for MDS and acute myeloid leukaemia, fell 8.2% to $154 million due to generic competition in the USA.

Chief executive Bob Hugin said “"2014 was an outstanding year for Celgene, adding that “significant operating momentum along with a number of key milestones provide great opportunity for 2015 and beyond”. First up, regulators on both sides of the Atlantic are expected to decide whether Revlimid can be used for newly diagnosed multiple myeloma, which would boost its already-impressive sales.

For 2015, sales are expected to be $9-$9.5 billion, an increase of 22.3% and that forecast includes a negative currency impact of around $100 million.